Product
BT-001
Name
BT-001
1 clinical trial
6 indications
Indication
Metastatic CancerIndication
Soft Tissue SarcomaIndication
Merkel Cell CarcinomaIndication
MelanomaIndication
Triple-Negative Breast CancerIndication
Lung CancerClinical trial
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.Status: Recruiting, Estimated PCD: 2025-04-30